noom weight loss glp-1 Microdosing for Noom’s New Microdose GLP-1 Program

For most people, its uncomfortable rather than dangerous, and symptoms often improve over time or after a dose adjustment

A decade from now, the most popular GLP-1 drugs might advertise weight loss as a secondary benefit

Traditional use in cosmetic formulations does not establish efficacy for metabolic or appetite-related outcomes

A few risks in the market are safety concerns and side effects, and strict regulatory scrutiny

If this revolutionary treatment could help you live longer by fighting obesity, diabetes, and arthritis all at once, whats standing in your way

Medicares co-pay of $50 will be higher than the co-pay typically offered by private insurance companies, which is usually around $25 or less